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Pathogenesis of chronic obstructive
pulmonary disease (COPD)
The World Congress on Lung Health and 10th ERS
Annual Congress brought together a wide range of scien-
tists involved in studies on the pathogenesis of COPD.
The research that was presented in various oral and
poster presentations included a variety of approaches,
including cell biology studies, analysis of lung tissue and
studies of exhaled breath. The following report describes a
selection of new developments related to research on the
pathogenesis of COPD that were presented during the
Florence meeting.
Oxidative stress in COPD
Whereas it is evident that cigarette smoke exposure
results in oxidative stress, it is also clear that the inflamma-
tory process observed in patients with COPD, asthma or
cystic fibrosis, for example, results in disturbance of the
oxidant—antioxidant balance. Several presentations
focused on the alterations in cellular functioning that
results from oxidative stress, the body’s antioxidant
systems and methods to detect oxidative stress in tissue
and exhaled breath. From presentations of Barnes and co-
workers (London, UK) and other research groups, it is
clear that the analysis of exhaled breath condensate might
form an attractive, non-invasive method for studying oxida-
tive stress. However, it is also evident that many method-
ological issues still remain to be resolved before highly
reproducible methods can be introduced. After the reports
of some years ago on increased levels of hydrogen perox-
ide in exhaled breath condensate of patients with COPD,
other markers of oxidative stress in breath condensate
have now been introduced, including nitrosylated tyrosine
residues. Data from the research group of Kharitonov and
Barnes (London, UK) in asthma patients revealed that
nitrotyrosine in exhaled breath condensate is increased in
patients with asthma, and decreased on treatment with
high-dose steroids. Treatment of asthma patients or
healthy controls with an inhaled nitric oxide (NO) synthesis
inhibitor decreased both exhaled NO and nitrotyrosine in
exhaled breath condensate, suggesting that nitrotyrosine
in exhaled breath condensate results from endogenous
(pulmonary) NO synthesis. In addition, levels of the lipid
peroxidation marker 8-isoprostane too were increased in
patients with inflammatory lung disease, and highest levels
were found in patients with cystic fibrosis. It is interesting
to note that orally administered antioxidants might not
affect exhaled markers of oxidative stress.
Metalloproteinases
Various studies focused on the role of metallopro-
teinases and their inhibitors. Layton (Oxford, UK) gave a
comprehensive review of the various members of the
metalloproteinase family and their natural inhibitors, and
discussed strategies for the development of inhibitors. A
combined matrix metalloproteinase (MMP) and sheddase
inhibitor was found to be active in rodent models of aller-
gic asthma. D’Ortho (Créteil, France) discussed the role
of MMPs in pulmonary vascular remodelling and pul-
monary hypertension. Animal models for pulmonary
hypertension were discussed in which MMP activity was
altered by gene transfer of the MMP inhibitor tissue
inhibitor of metalloproteinases-1 (TIMP-1) or TIMP-1
knockout mice. On the basis of these data the conclu-
sion was drawn that MMPs might serve a protective role
in pulmonary hypertension. These data seemed to be in
contrast to recently published data in another animal
model in which serine proteinase and MMP inhibitorshttp://respiratory-research.com/content/1/3/178
c
o
m
m
e
n
t
a
r
y
r
e
v
i
e
w
r
e
p
o
r
t
s
p
r
i
m
a
r
y
 
r
e
s
e
a
r
c
h
were found to block vascular intimal thickening. Shapiro
(St Louis, Missouri, USA) reviewed the well-known study
from his laboratory showing the involvement of mouse
macrophage elastase (MMP-12) in the development of
cigarette-smoke-induced emphysematous lesions in mice.
Subsequent studies now showed that treatment of mice in
this model with a MMP inhibitor protects the mice against
the development and progression of emphysema.
Whereas these data suggest a predominant role for MMP
in the development of smoke-induced emphysema, neu-
trophil elastase knockout mice too were found to develop
less emphysema. These data suggest a role for both neu-
trophil-derived elastase and macrophage elastase in
emphysema. In addition, the major role of neutrophil elas-
tase in the antibacterial activity of the mouse neutrophil
(that lacks the antimicrobial defensins that are characteris-
tic of the antimicrobial armature of the neutrophil in other
mammals and humans) was discussed.
Inflammation in COPD
There is evidence for the involvement of a wide range of
cell types in the pathogenesis of COPD, including neu-
trophils, macrophages and CD8+ T cells. Neutrophilic
inflammation is observed in patients with a1-proteinase
inhibitor (a1-PI) deficiency. Because a1-PI not only acts as
an inhibitor of neutrophil serine proteinases such as
neutrophil elastase, but also inhibits the cytotoxic and anti-
microbial peptides neutrophil defensins, Wencker (Essen,
Germany) studied neutrophil defensin levels in patients
with a1-PI deficiency. Increased neutrophil defensin levels
were found in the epithelial lining fluid of a1-PI deficiency
patients, levels that correlated with neutrophil numbers
and interleukin-8 levels. These observations lend further
support to the hypothesis that neutrophil defensins might
be one of the neutrophil products involved in the patho-
genesis of emphysema associated with a1-PI deficiency.
Therefore the treatment of patients with a1-PI deficiency
with a1-PI, for instance with the use of a1-PI inhalation as
reported by Vogelmeier (Munich, Germany), might poten-
tially inhibit the proinflammatory activities of neutrophil
defensins in addition to inhibiting neutrophil elastase.
The observations reported by Frankenberger (Munich,
Germany) demonstrated an interesting approach to the
study of macrophages in COPD. Analysis of induced
sputum demonstrated that there is an increased propor-
tion of CD14+ CD16+ macrophages in induced sputum
from COPD patients. Because studies in peripheral blood
have shown that CD14+ CD16+ monocytes represent a
subpopulation of macrophages with a high proinflamma-
tory activity, these studies indicate a novel approach to the
study of macrophages in COPD. Eosinophilic inflamma-
tion has been found to be associated with exacerbations
of chronic bronchitis. Qiu (London, UK) studied the
expression of putative eosinophil chemotactic chemokines
in exacerbations of chronic bronchitis, and showed an
increase in eosinophil numbers and RANTES expression
(shown by in situ hybridization) in bronchial biopsies of
patients with chronic bronchitis during exacerbations. A
trend towards an increase in MCP-4 and eotaxin expres-
sion was noted. The capacity of sputum from COPD
patients to induce the migration of neutrophils in vitro
across a double layer of cultured epithelial and endothelial
cells was used by van Overveld (Antwerp, Belgium) to
assess the anti-inflammatory effect of treatments with
inhaled steroids or N-acetylcysteine. Treatment of patients
with these drugs reduced the extent of sputum-induced
neutrophil transmigration. Whereas steroids were active
after 2 months of treatment and were ineffective after pro-
longed treatment (more than 4 months), N-acetylcysteine
treatment was effective only after prolonged treatment
(more than 4 months).
Conclusion
New treatment strategies for COPD are being developed
and evaluated in preclinical and clinical models. Treat-
ments such as those with antioxidants and with MMP or
serine proteinase inhibitors were discussed elsewhere in
this report. One other class of promising new drugs is the
selective phosphodiesterase (PDE) inhibitors. These
drugs are considered to be potentially useful in the treat-
ment of COPD and asthma. Various studies described
activities of selective PDE4 inhibitors that might further
support their use in the treatment of COPD. A PDE4
inhibitor was found to inhibit mucin expression in an animal
model of challenge with ovalbumin, whereas cell culture
studies in vitro revealed inhibitory effects on processes
such as smooth muscle proliferation in human airway and
fibroblast-mediated collagen degradation. From these and
similar studies, it is evident that appropriate cell culture
and animal models might help in the development of novel
and innovative ways to treat COPD.
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